DMU-212 | Anticancer Compound | MCE - MCE-生物活性分子大师
DMU-212 是一种白藜芦醇 (HY-16561) 甲基化衍生物，具有抗分裂、抗增殖、抗氧化和促进细胞凋亡的活性。 DMU-212 通过诱导凋亡 (apoptosis) 和激活 ERK1/2 蛋白导致有丝分裂停止。 …
DMU-212 3,4,5,4'-四甲氧基二苯乙烯 |CAS 134029-62-2 - 翌圣生物
DMU-212 (DMU212) 是一种 可口服的 白藜芦醇甲基化衍生物，具有抗增殖、抗分裂、抗氧化 和抗肿瘤作用 。 此外， DMU-212 还能通过 诱导caspase依赖性凋亡和激活ERK1/2 来抑制 有丝 …
Trans-3,4,5,4′-tetramethoxystilbene, a resveratrol analog ... - Nature
2013年6月17日 · Trans -3,4,5,4′-tetramethoxystilbene (DMU-212) has shown strong antiproliferative activities against a variety of cancer cells. The aim of this study was to …
DMU-212 | Apoptosis | ERK | TargetMol
DMU-212, a methylated form of Resveratrol, shows antimitotic, antiproliferative, and antioxidant activities. DMU-212 induces mitotic arrest through the activation of ERK1/2 protein and the …
- 评论数: 10
DMU-212 | Anticancer Compound - MedChemExpress
DMU-212 is a methylated derivative of Resveratrol (HY-16561), with antimitotic, anti-proliferative, antioxidant and apoptosis promoting activities. DMU-212 induces mitotic arrest via induction of …
DMU-212 against EGFR-mutant non-small cell lung cancer via
2023年4月26日 · The data found that the cytotoxicity of DMU-212 on three EGFR-mutant NSCLC cell lines was significantly higher than that of normal lung epithelial cell. Further study showed …
DMU-212 inhibits tumor growth in xenograft model of human …
DMU-212 has been shown to evoke a mitochondrial apoptotic pathway in transformed fibroblasts and breast cancer. However, recently published data indicated the ability of DMU-212 to evoke …
2022年9月19日 · DMU-212, an analog of resveratrol, has been reported to have significant inhibitory effects on several types of cancer. However, the effect of DMU-212 on lung cancer …
Heteroaromatic analogs of the resveratrol analog DMU-212 as …
2015年7月7日 · Novel heteroaromatic DMU-212 analogs (8–15) have been synthesized and evaluated for their anti-cancer activity against a panel of 60 human cancer cell lines. …
DMU-212 (DMU-212) - 在研适应症：肿瘤_专利_临床_研发
DMU-212，由De Montfort University (De Montfort University)公司最早进行研发，目前全球最高研发状态为临床前，治疗领域: 肿瘤，在研适应症: 肿瘤，在研机构: De Montfort University。